Trials / Completed
CompletedNCT03126019
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib tablets administered orally with water and without regard to food |
Timeline
- Start date
- 2018-03-14
- Primary completion
- 2021-02-26
- Completion
- 2024-06-07
- First posted
- 2017-04-24
- Last updated
- 2025-03-14
- Results posted
- 2022-02-10
Locations
83 sites across 13 countries: United States, Australia, Canada, Czechia, Denmark, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03126019. Inclusion in this directory is not an endorsement.